Invitation to a Presentation of the 1st Quarter 2022 Results

Oncoinvent would like to extend an invitation to a presentation of the Q1 2022 results. The presentation will be held on Wednesday 1. June 2022 at 08:30 AM in the offices of the company at Gullhaugsveien 7, Oslo, 3rd Floor.

To attend, please register with

Oncoinvent ønsker med dette å invitere til presentasjon av resultater for 1. kvartal 2022. Presentasjonen vil holdes onsdag 1. juni 2022, kl. 08:30 i selskapets lokaler i Gullhaugsveien 7, Oslo, 3. etasje.

Vi ber om at deltakere registrerer seg ved å sende en e-post til

Organiser: Oncoinvent

Gullhaugsveien 7, Oslo, 3rd Floor.

Date: 1 June 2022

Anders Månsson

Chief Executive Officer

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.